0.3684
6.32%
0.028
アフターアワーズ:
.37
0.0016
+0.43%
前日終値:
$0.3404
開ける:
$0.34
24時間の取引高:
1.53M
Relative Volume:
0.68
時価総額:
$58.05M
収益:
-
当期純損益:
$-101.17M
株価収益率:
-0.3542
EPS:
-1.04
ネットキャッシュフロー:
$-96.57M
1週間 パフォーマンス:
-11.73%
1か月 パフォーマンス:
-27.04%
6か月 パフォーマンス:
-59.64%
1年 パフォーマンス:
-54.82%
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
XFOR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
XFOR | 0.3702 | 58.05M | 0 | -101.17M | -96.57M | -1.04 |
VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-08-30 | 再開されました | B. Riley Securities | Buy |
2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
2022-12-12 | 開始されました | Piper Sandler | Overweight |
2019-12-23 | 開始されました | Oppenheimer | Outperform |
2019-12-18 | 開始されました | ROTH Capital | Buy |
2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
2019-12-05 | 開始されました | B. Riley FBR | Buy |
2019-06-07 | 開始されました | Stifel | Buy |
2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Atenolol Global Market 2024 – Top Manufacturers, Latest Trends, Future Prospects And Outlook By 2033 - WhaTech
B. Riley Predicts Increased Earnings for X4 Pharmaceuticals - Defense World
Spotlight On 3 US Penny Stocks With At Least $60M Market Cap - Simply Wall St
B. Riley Expects Stronger Earnings for X4 Pharmaceuticals - MarketBeat
Top 10 pharma companies in India by market cap [2024] - Forbes India
Benzodiazepine Drugs Market Overview: Industry Insights, Demand Trends, Competitive Landscape, and Key Inno... - WhaTech
Chronic Pain Market Set for Steady Growth with 4% CAGR Driven by Drugs and Devices | Future Market Insights, Inc. - GlobeNewswire
10 Biggest Biotechnology Companies - Investopedia
HC Wainwright Predicts Lower Earnings for X4 Pharmaceuticals - MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2024 Earnings Call Transcript - Insider Monkey
RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters.com
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary - Fast Company
Earnings call: X4 Pharmaceuticals reports progress in CN treatment By Investing.com - Investing.com Nigeria
CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28% - Simply Wall St
XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia… - Zacks Small Cap Research
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline - Quantisnow
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ... - Yahoo Finance
X4 Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle
Stifel cuts X4 Pharmaceuticals target to $4, maintains Buy - Investing.com
X4 Pharmaceuticals: Promising Phase 2 Trial Results - TipRanks
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) - Marketscreener.com
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World
Xenon Reports Q3 2024 Financial Results and Business Update - The Manila Times
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Quantisnow
Great week for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) institutional investors after losing 18% over the previous year - Simply Wall St
X4 Pharmaceuticals Inc (XFOR) Has A Gold Mine On Its Hands - Stocks Register
Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 | DelveInsight - The Malaysian Reserve
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - GlobeNewswire
Ionis to present at upcoming investor conferences - Quantisnow
Glenmark Pharmaceuticals Ltd. Sees -4.19% Decline in Stock Price, Rated 'Hold' by MarketsMOJO - MarketsMojo
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - Quantisnow
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
Global Molecular Modeling Market to Hit USD 19.47 Billion by 2032, Driven by Demand for Drug Discovery Innovation and Advanced Computational Tools | Research by SNS Insider - 新浪香港
X4 Pharmaceuticals (XFOR) to Release Earnings on Wednesday - MarketBeat
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition - Quantisnow
Vanguard Group Inc's Strategic Acquisition in X4 Pharmaceuticals Inc - GuruFocus.com
Top 50 Pharma: Oncology patent leaders 2024 - Drug Discovery & Development
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow
H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - The Manila Times
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 - PR Newswire
Sun Pharma shares tumble 4% as US court blocks Leqselvi launch - The Economic Times
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - The Manila Times
9 Best Biotech Stocks Of November 2024 - Forbes
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):